At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
SPN-810 +3 moredrug
Likely dose
SPN-810 1.67mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of SPN-810 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems
In Brief
A Phase 2 clinical trial evaluating SPN-810 for Attention Deficit Disorder With Hyperactivity and Conduct Disorder. Completed, enrolled 78 participants across 9 sites.
Detailed Summary
The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartOct 2008
Primary CompletionSep 2009
TodayJul 2026
First PostedFeb 29, 2008
Enrollment StartOct 21, 2008
Primary CompletionSep 23, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.3 years ago
Interventions
SPN-810drug
1.67mg capsule taken TID
SPN-810drug
3.33mg capsule taken TID
SPN-810drug
5mg capsule taken TID
SPN-810drug
6.67 mg capsule taken TID